Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of atogepant in pediatric migraine
2022-501099-24-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine, sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of atogepant, Clinical laboratory testing and 6 more. Planned start Dec 2023; status: authorised.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2022-501099-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501099-24-00.